Literature DB >> 35766433

Antibody deposition on vascular endothelial cells contributes to localized inflammation in salivary glands.

Harini Bagavant1, Marta Trzeciak1, Indranil Biswas1, Joanna A Papinska1, Katarzyna Cizio1, Umesh S Deshmukh1.   

Abstract

BACKGROUND: Oral and ocular dryness due to reduced saliva and tear production, exocrine gland inflammation, and autoantibodies to multiple cellular proteins are the cardinal features of Sjögren's Disease. Among the autoantibody specificities, anti-Ro52 is linked with higher disease severity. We have previously reported that mice immunized with recombinant Ro52 developed IgG deposits in salivary and lacrimal glands and showed reduced saliva and tear production. Furthermore, passive transfer of sera from Ro52-immunized mice rapidly induced glandular dysfunction without immune cell infiltration in recipient mice.
METHODS: To identify mechanisms driving antibody-mediated salivary gland dysfunction, hyperimmune rabbit antiserum to mouse Ro52 was passively transferred into NZM2758 female mice, pretreated with alum adjuvant. Alum-pretreated mice given hyperimmune rabbit antiserum to maltose-binding protein served as controls. Antibody deposition and its distribution in the salivary glands were studied by immunofluorescence staining for rabbit IgG, nerve fibers, and endothelial cells. The nCounter inflammation panel was used to determine differentially expressed genes in the salivary gland.
RESULTS: Rabbit IgG deposits were detected in salivary glands of anti-Ro52 immune sera recipients. The rabbit IgG was present on the endothelial cells in small blood vessels, and it did not co-localize with nerve fibers. Ingenuity pathway analysis of the gene expression dataset predicted the canonical vascular endothelial growth factor (VEGF) pathway as the most activated and Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) as the most inhibited pathway in the salivary glands of anti-Ro52 sera recipients.
CONCLUSION: Our study suggests that autoantibody deposition on salivary gland endothelial cells might play a critical role in the pathogenesis of Sjögren's Disease.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Ro52; Sjögren's disease; autoantibody; endothelial cells; salivary glands

Mesh:

Substances:

Year:  2022        PMID: 35766433      PMCID: PMC9388553          DOI: 10.1111/jop.13330

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   3.539


  10 in total

1.  Interaction between innate immunity and Ro52-induced antibody causes Sjögren's syndrome-like disorder in mice.

Authors:  Barbara M Szczerba; Paulina Kaplonek; Nina Wolska; Anna Podsiadlowska; Paulina D Rybakowska; Paromita Dey; Astrid Rasmussen; Kiely Grundahl; Kimberly S Hefner; Donald U Stone; Stephen Young; David M Lewis; Lida Radfar; R Hal Scofield; Kathy L Sivils; Harini Bagavant; Umesh S Deshmukh
Journal:  Ann Rheum Dis       Date:  2015-02-05       Impact factor: 19.103

2.  Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands.

Authors:  Silvia Reina; Leonor Sterin-Borda; Daniela Passafaro; Enri Borda
Journal:  Arch Oral Biol       Date:  2011-03-03       Impact factor: 2.633

3.  Immune response against the coiled coil domain of Sjögren's syndrome associated autoantigen Ro52 induces salivary gland dysfunction.

Authors:  Magdalena Sroka; Harini Bagavant; Indranil Biswas; Abigail Ballard; Umesh S Deshmukh
Journal:  Clin Exp Rheumatol       Date:  2018-01-31       Impact factor: 4.473

4.  Association between genetic variants in the tumour necrosis factor/lymphotoxin α/lymphotoxin β locus and primary Sjogren's syndrome in Scandinavian samples.

Authors:  Anne Isine Bolstad; Stephanie Le Hellard; Gudlaug Kristjansdottir; Lilian Vasaitis; Marika Kvarnström; Christopher Sjöwall; Svein Joar Auglænd Johnsen; Per Eriksson; Roald Omdal; Johan G Brun; Marie Wahren-Herlenius; Elke Theander; Ann-Christine Syvänen; Lars Rönnblom; Gunnel Nordmark; Roland Jonsson
Journal:  Ann Rheum Dis       Date:  2012-01-30       Impact factor: 19.103

Review 5.  Disease mechanisms in Sjögren's syndrome: What do we know?

Authors:  Roland Jonsson
Journal:  Scand J Immunol       Date:  2022-02-01       Impact factor: 3.487

6.  Xerostomia in Sjögren's syndrome and lupus erythematosus: a comparative histological and immunofluorescence study of minor salivary glands alterations.

Authors:  Juliana Dumêt Fernandes; Marcello Menta S Nico; Valéria Aoki; Sheyla Bologna; Ricardo Romiti; Mauricio Levy-Neto; Sílvia Vanessa Lourenço
Journal:  J Cutan Pathol       Date:  2009-07-15       Impact factor: 1.587

7.  Similar synapse elimination motifs at successive relays in the same efferent pathway during development in mice.

Authors:  Shu-Hsien Sheu; Juan Carlos Tapia; Shlomo Tsuriel; Jeff W Lichtman
Journal:  Elife       Date:  2017-02-03       Impact factor: 8.140

8.  Immune Response Targeting Sjögren's Syndrome Antigen Ro52 Suppresses Tear Production in Female Mice.

Authors:  Marta Trzeciak; Harini Bagavant; Joanna Papinska; Umesh S Deshmukh
Journal:  Int J Mol Sci       Date:  2018-09-27       Impact factor: 5.923

9.  Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice.

Authors:  Margaret K Gatumu; Kathrine Skarstein; Adrian Papandile; Jeffrey L Browning; Roy A Fava; Anne Isine Bolstad
Journal:  Arthritis Res Ther       Date:  2009-02-18       Impact factor: 5.156

Review 10.  Autoantibodies against muscarinic acetylcholine receptor M3 in Sjogren's syndrome and corresponding mouse models.

Authors:  Xinhua Yu; Gabriela Riemekasten; Frank Petersen
Journal:  Front Biosci (Landmark Ed)       Date:  2018-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.